Penn Medicine Reports First Clinical Safety Data for Multi-Chain KIR-CAR T Therapy Targeting Advanced Solid Tumors

University of Pennsylvania trial finds novel KIR-CAR T therapy safe for solid tumors. Learn how the "on-off" switch prevents T cell exhaustion in cancer.

By: AXL Media

Published: Apr 21, 2026, 4:41 AM EDT

Source: Information for this report was sourced from University of Pennsylvania School of Medicine

Engineering a Solution for Solid Tumor Challenges

While CAR T cell therapy has revolutionized the treatment of liquid blood cancers, its application in solid tumors has been hampered by T cell exhaustion and off-target toxicity. To address these hurdles, a team led by Dr. Janos L. Tanyi at the Perelman School of Medicine has pioneered the use of KIR-CAR technology. Unlike traditional "single-chain" CAR T designs that remain constantly active—and thus prone to "burning out"—the KIR-CAR model utilizes a multi-chain structure inspired by natural killer (NK) cells. This design separates the antigen-recognition and cell-activation functions, allowing the T cell to remain in a resting state until it specifically encounters a tumor cell, significantly extending its functional lifespan.

The Multi-Chain "On-Off" Mechanism

The investigational therapy, SynKIR-110, targets mesothelin, a protein frequently overexpressed in aggressive cancers such as ovarian cancer, mesothelioma, and cholangiocarcinoma. The multi-chain KIR-CAR provides a natural "on-off" switch; the CAR turns on to engage and kill the target and then reverts to a resting state. This rhythmic activity mimics natural immune responses, effectively preventing the problem of chronic activation that typically leads to T cell exhaustion. Furthermore, this controlled activation limits the risk of the therapy attacking healthy cells, thereby reducing the likelihood of severe immune-related adverse events.

Early Efficacy in Relapsed Patient Populations

The STAR-101 trial reported data from nine patients who had previously failed an average of four different lines of standard therapy, including surgery and chemotherapy. Despite the advanced stage of their diseases, the trial observed a 44 percent disease stabilization rate across the cohorts. Notably, one patient in the highest dose group achieved a partial response that is currently ongoing. These early efficacy signals are particularly encouraging for cancers like ovarian cancer, which has a 70 percent recurrence rate and lacks approved cellular therapy options.